Digital Implementation of the German S3 Clinical Practice Guideline for Multimorbidity

NCT06831994 · tracked via the Priya Life Science Germany tracker

Sponsor

Universitätsklinikum Hamburg-Eppendorf

Phase

Not applicable

Started

2025-02-26

Last updated

2026-05-29

Condition(s) studied

Asthma BronchialeBreast NeoplasmsCoronary DiseaseDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Pulmonary Disease, Chronic ObstructiveObesityHeart FailureChronic Low-back PainDepressionOsteoporosisRheumatoid ArthritisComorbidities and Coexisting Conditions

Investigational drug(s) / intervention(s)

gp-multitool.de

gp-multitool.de: The intervention is based on the digital tool gp-multitool.de. The GPs can send questionnaires by email to patients and patients can fill out questionnaires at their home or in the waiting room of the practice using any digital device with browser and access to the internet. The digital tool also includes instructions for conducting a medication review. Results will be available from the computers of attending GPs. Decisions from talks between GPs and patients can be documented in the tool. The tool includes ten questionnaires: 1. patient preferences (including a. treatment goals, and b. involvement of other persons in decision making); 2. social life (including a. activities and participation, and b. social support); 3. treatment situation (including a. problems with medication, and b. treatment burden); 4. health complaints (including a. pain, b. psychiatric disorders, and c. other complaints). 5. resilience and protective behavior against heat.

Study summary

The web application gp-multitool.de is a digital tool for implementing the German S3 clinical practice guideline for multimorbidity of the German Society of General Practitioners and Family Physicians in primary care. The tool enhances evidence-based and patient-centered care by assessing and providing information relevant for the primary care of this patient group. This cluster-randomised clinical evaluation study examines the effectiveness of an intervention based on gp-multitool.de in general practitioner (GP) practices in Germany.

Eligibility

Sex

ALL

Min age

65 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * participation in a disease management program (DMP); in Germany, DMPs have been implemented in outpatient care for asthma, breast neoplasms, coronary heart disease, diabetes mellitus type 1, diabetes mellitus type 2, chronic obstructive pulmonary disease, obesity, heart failure, chronic low back pain, depression, osteoporosis, rheumatoid arthritis * at least two of the following coexisting conditions: Hypertension, Lipid metabolism disorders, Chronic low back pain, Severe vision reduction, Joint arthrosis, Diabetes mellitus, Chronic ischemic heart disease, Thyroid dysfunction, Cardiac arrhythmias, Obesity, Hyperuricemia/Gout, Prostatic hyperplasia, Lower limb varicosis, Liver diseases, Depression, Asthma/Chronic obstructive pulmonary disease, Gynaecological problems, Atherosclerosis/Peripheral arterial occlusive disease, Osteoporosis, Renal insufficiency, Cerebral ischemia/Chronic stroke, Cardiac insufficiency, Severe hearing loss, Chronic cholecystitis/Gallstones, Somatoform disorders, Hemorrhoids, Intestinal diverticulosis, Rheumatoid arthritis/Chronic polyarthritis, Cardiac valve disorders, Neuropathies, Dizziness, Dementias, Urinary incontinence, Urinary tract calculi, Anemias, Anxiety, Psoriasis, Migraine/chronic headache, Parkinson's disease, Cancers, Allergies, Chronic gastritis/Gastroesophageal reflux disease, Sexual dysfunction, Insomnia, Tobacco abuse, Hypotension Exclusion Criteria: * no capacity to consent * functional limitations precluding participation in the intervention (eg, loss of vision) * functional limitations precluding participation in telephone interviews (eg, loss of hearing) * limited German language skills precluding participation in telephone interviews * participation in other trials during the observation time of the evaluation study

Primary outcome measure(s)

Whether patients have stayed at least once for at least one night in hospital during the preceding twelve months — Once at baseline (before randomization of practices) and once at follow-up (immediately after the intervention)
The outcome will be assessed by a standardised questionnaire. The patients will be asked how often they had been in hospital during the preceding twelve months and how long these stays had lasted. Before analysis, the outcome will be dichotomised.

Trial sites (1)

Facility	City	Region	Status
Universitätsklinikum Hamburg-Eppendorf	Hamburg	Germany

More Universitätsklinikum Hamburg-Eppendorf trials in Germany

External Validation of the MASCAN Score for the Classification of Difficult Mask Ventilation Recruiting

Characterisation of phenotYpes in aCute Heart faiLure patiEnts Recruiting

Prospective Registry and Biobank for Long-term Observational Studies in Adult Patients with Pulmonary Hypertension Recruiting

Proof of Concept Human Study: Dietary Intervention to Modify Intestinal Inflammation in IBD Active, not recruiting

Cerebellar Transcranial Alternating Current Stimulation (tACS) to Modulate Parkinson's Disease Tremor Recruiting

Other trials for the same condition

A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer Active, not recruiting

A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients Recruiting

The Impact of Hormonal Contraceptive Use and Lifestyle Factors on Fracture Risk and Bone Quality in Young Female Adults Recruiting

Effects of Negative Pressure Ventilation Onto Hemodynamics and Right Ventricular Funktion in Patients After Implantation of a Left Ventricular Assist Device. Recruiting

Multicentric Approval Study Trans-Duodenal Barrier for Typ 2 Diabetes With Obesity Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06831994 on ClinicalTrials.gov ↗ ← All trials in Germany